drugset
Drugs / allogeneic human dental pulp stem cells
last change Dec 2021 re-read 3 minutes ago

allogeneic human dental pulp stem cells

also known as DPSCs
Developed for
COVID-19
Investigated by
Beijing SH Bio-Tech Corporation, Beijing (CN) · Renmin Hospital of Wuhan University · Utooth Biological Technology Co., Ltd. Hubei (CN)

Trials 1

today NCT04336254 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04336254 May 2020 → Nov 2021 COVID-19 Renmin Hospital of Wuhan University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as allogeneic human dental pulp stem cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04336254 ↗
Known as DPSCs “allogeneic human dental pulp stem cells (DPSCs)” PMID 32532356 ↗ Jun 2020
Route Intravenous “The experimental group will receive an intravenous injection of dental pulp stem cells suspension” PMID 32532356 ↗ Jun 2020